New research, funded in part by KCCure, indicates that IL-15 may be a potential treatment option for patients with Chromophobe Renal Cell Carcinoma (ChRCC). There are currently a number of phase 1 trials testing various forms of IL-15 in patients with metastatic disease from solid tumors. We will try to keep this list updated as more trials become available.
| Trial Identifier/Link | IL-15 Agent | Delivery/Design | Sponsor | Location(s) |
|---|---|---|---|---|
| NCT04250155 | XmAb24306 | Arm 1: XmAb24306 as a single agent. Arm 2: XmAb23406 in combination with PD-L1 inhibitor atezolizumab | Genentech | United States: AZ, CA, CT, TN Australia, Canada, Korea, the Netherlands |
| NCT03388632 | Recombinant Interleukin 15 | Arm 1: IL-15 in combination with nivolumab (Opdivo) Arm 2: IL-15 in combination with ipilimumab (Yervoy) Arm 3: IL-15 in combination with nivolumab and ipilimumab | National Cancer Institute (NCI) | Bethesda, MD |
| NCT05322408 | HCW9218 | Single arm: HCW9218 is injected subcutaneously every three weeks | Masonic Cancer Center, University of Minnesota | Minneapolis, MN |
| NCT04898543 | N-803 | Autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK) - with N-803 | ImmunityBio | El Segundo, CA |